chartexchange

URGN
UroGen Pharma Ltd.
stockNASDAQ

At CloseNov 18, 2026 3:59:59 PM EST
29.78USD-0.285%(-0.09)1,144,210
Pre-marketNov 18, 2026 9:27:30 AM EST
29.60USD-0.904%(-0.27)
After-hoursNov 18, 2026 4:45:30 PM EST
30.22USD+1.460%(+0.43)
Loading…
Loading…
Healthcare
Biotechnology
HQ
Princeton, NJ, USA
Previous Close
$29.87
Beta
1.18
52-Week High
$50.81 2026-08-19
52-Week Low
$16.50 2026-03-30
SMA 50
$36.10
SMA 200
$31.83
Avg. Vol 10D
1.69M
Avg. Vol 30D
1.44M
Avg. Vol 90D
1.03M
Relative Vol
0.80
43.58M
0.3800%
146,112
URGN Profile

urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra'anana, israel with u.s. headquarters in new york.

URGN Performance
PeriodPriceDateChangeBeta
1W26.392026-11-12+12.87%-5.212
1M34.152026-10-19-12.78%0.491
3M50.292026-08-19-40.77%0.887
6M28.262026-05-19+5.40%0.888
1Y25.272025-11-19+17.87%1.182
2Y11.162024-11-19+166.89%—
5Y12.062021-11-19+146.97%0.929
URGN Stock Summary

UroGen Pharma Ltd. (NASDAQ:URGN) stock price today is $29.79, and today's volume is 1,144,210. URGN is down 0.285% today. The 30 day average volume is 1.44M. URGN market cap is $1.46B with 49.05M shares outstanding.